Samuel J Klempner1,2, Munveer S Bhangoo3, Hubert Y Luu4, Seung Tae Kim5, Joseph Chao6, Kyoung-Mee Kim7, Jeeyun Lee5. 1. The Angeles Clinic and Research Institute, Los Angeles, CA, USA. 2. Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA. 3. Division of Hematology Oncology, Scripps Clinic, La Jolla, CA, USA. 4. Department of Surgery, University of California, San Francisco, CA, USA. 5. Department of Medicine, Samsung Medical Center, Seoul, Korea. 6. Department of Medical Oncology and Therapeutics Research, City of Hope Comprehensive Cancer Center, Duarte, CA, USA. 7. Department of Pathology and Translational Genomics, Samsung Medical Center, Seoul, Korea.
Abstract
BACKGROUND: Gastric cancer (GC) is a leading cause of cancer-specific mortality with limited biologically informed treatments. The ataxia telangiectasia mutated (ATM) gene is critically involved in the repair of double-stranded DNA breaks and a component of DNA damage repair (DDR) pathways. Platinum salts are hypothesized to have increased efficacy in tumors deficient in DDR pathways. We sought to investigate an association between ATM status and response to XELOX in a homogenous first line GC patient cohort. METHODS: A clinically annotated cohort of 137 Korean patients with advanced GC treated with first-line XELOX was retrospectively examined for ATM status by immunohistochemistry. Correlation between ATM expression and clinicopathologic variables was performed by two-tailed, unpaired t-tests and Fisher's exact tests. Kaplan-Meier survival analysis curves and Cox proportional hazards models were used to evaluate for independent predictors of disease-free survival (DFS) and overall survival (OS). RESULTS: Low ATM expression was observed in 19.0% (26/137) of patients and was not associated with clinicopathologic features or response rate to XELOX. Univariate, but not multivariable, logistic regression and Cox analysis identified ATM as an independent risk factor influencing OS and DFS. A higher ECOG score independently predicted worse survival [hazard ratio (HR) 2.96, P=0.016] and complete surgical resection independently protected against progression of disease (HR 0.69, P=0.007). CONCLUSIONS: Low ATM expression was not associated with increased response rates to XELOX in a single-institution cohort of advanced GC patients. Similarly, ATM status did not predict DFS or OS after platinum-based chemotherapy.
BACKGROUND: Gastric cancer (GC) is a leading cause of cancer-specific mortality with limited biologically informed treatments. The ataxia telangiectasia mutated (ATM) gene is critically involved in the repair of double-stranded DNA breaks and a component of DNA damage repair (DDR) pathways. Platinum salts are hypothesized to have increased efficacy in tumors deficient in DDR pathways. We sought to investigate an association between ATM status and response to XELOX in a homogenous first line GC patient cohort. METHODS: A clinically annotated cohort of 137 Korean patients with advanced GC treated with first-line XELOX was retrospectively examined for ATM status by immunohistochemistry. Correlation between ATM expression and clinicopathologic variables was performed by two-tailed, unpaired t-tests and Fisher's exact tests. Kaplan-Meier survival analysis curves and Cox proportional hazards models were used to evaluate for independent predictors of disease-free survival (DFS) and overall survival (OS). RESULTS: Low ATM expression was observed in 19.0% (26/137) of patients and was not associated with clinicopathologic features or response rate to XELOX. Univariate, but not multivariable, logistic regression and Cox analysis identified ATM as an independent risk factor influencing OS and DFS. A higher ECOG score independently predicted worse survival [hazard ratio (HR) 2.96, P=0.016] and complete surgical resection independently protected against progression of disease (HR 0.69, P=0.007). CONCLUSIONS: Low ATM expression was not associated with increased response rates to XELOX in a single-institution cohort of advanced GC patients. Similarly, ATM status did not predict DFS or OS after platinum-based chemotherapy.
Authors: P M L H Vencken; M Kriege; D Hoogwerf; S Beugelink; M E L van der Burg; M J Hooning; E M Berns; A Jager; M Collée; C W Burger; C Seynaeve Journal: Ann Oncol Date: 2011-01-12 Impact factor: 32.976
Authors: Kathryn Alsop; Sian Fereday; Cliff Meldrum; Anna deFazio; Catherine Emmanuel; Joshy George; Alexander Dobrovic; Michael J Birrer; Penelope M Webb; Colin Stewart; Michael Friedlander; Stephen Fox; David Bowtell; Gillian Mitchell Journal: J Clin Oncol Date: 2012-06-18 Impact factor: 44.544
Authors: Hee Sung Kim; Min A Kim; Darren Hodgson; Christopher Harbron; Robert Wellings; Mark J O'Connor; Christopher Womack; Xiaolu Yin; Yung-Jue Bang; Seok-Ah Im; Byung Lan Lee; Woo Ho Kim Journal: Pathobiology Date: 2013-01-15 Impact factor: 4.342
Authors: Elizabeth M Kass; Hildur R Helgadottir; Chun-Chin Chen; Maria Barbera; Raymond Wang; Ulrica K Westermark; Thomas Ludwig; Mary Ellen Moynahan; Maria Jasin Journal: Proc Natl Acad Sci U S A Date: 2013-03-18 Impact factor: 11.205
Authors: Shuhei Matsuoka; Bryan A Ballif; Agata Smogorzewska; E Robert McDonald; Kristen E Hurov; Ji Luo; Corey E Bakalarski; Zhenming Zhao; Nicole Solimini; Yaniv Lerenthal; Yosef Shiloh; Steven P Gygi; Stephen J Elledge Journal: Science Date: 2007-05-25 Impact factor: 47.728
Authors: Tomasz Byrski; Rebecca Dent; Pawel Blecharz; Malgorzata Foszczynska-Kloda; Jacek Gronwald; Tomasz Huzarski; Cezary Cybulski; Elzbieta Marczyk; Robert Chrzan; Andrea Eisen; Jan Lubinski; Steven A Narod Journal: Breast Cancer Res Date: 2012-07-20 Impact factor: 6.466
Authors: Tom Waddell; Ian Chau; David Cunningham; David Gonzalez; Alicia Frances Clare Okines; Alicia Frances; Clare Okines; Andrew Wotherspoon; Claire Saffery; Gary Middleton; Jonathan Wadsley; David Ferry; Wasat Mansoor; Tom Crosby; Fareeda Coxon; David Smith; Justin Waters; Timothy Iveson; Stephen Falk; Sarah Slater; Clare Peckitt; Yolanda Barbachano Journal: Lancet Oncol Date: 2013-04-15 Impact factor: 41.316
Authors: Michael Cerniglia; Joanne Xiu; Axel Grothey; Michael J Pishvaian; Yasmine Baca; Jimmy J Hwang; John L Marshall; Ari M VanderWalde; Anthony F Shields; Heinz-Josef Lenz; W Michael Korn; Mohamed Salem; Philip A Philip; Richard M Goldberg; Jia Zeng; Sunnie S Kim Journal: Mol Cancer Ther Date: 2021-11-01 Impact factor: 6.009
Authors: Song Ee Park; Hee Sung Kim; Eun-Jung Jung; Ja Hee Suh; Hyeyoung Min; Kyong-Choun Chi; Jong Won Kim; Joong-Min Park; In Gyu Hwang Journal: J Cancer Date: 2022-01-01 Impact factor: 4.207